Revive Therapeutics Ltd.CSE: RVV

Revive Therapeutics Announces Proposed Shares for Debt Settlement

· Issued by Revive Therapeutics Ltd. via ACCESS Newswire

Summary by 6ix AI

Revive Therapeutics Ltd., a life sciences company developing therapeutics for biodefence and pandemic preparedness, intends to issue up to 1,221,516 common shares at a deemed price of $0.05 per share to settle an aggregate of $61,061 in outstanding trade payables (unpaid bills).

Key details

  • The debt is owed to two arm's length creditors, meaning creditors not related to the company.
  • The shares will be issued under the policies of the Canadian Securities Exchange (CSE).
  • The shares will carry a statutory hold period of four months and one day from the date of issuance, during which they cannot be freely resold under applicable securities laws.

What’s still pending

  • Completion is subject to certain conditions, including receipt of all necessary regulatory approvals, including approval and acceptance by the Canadian Securities Exchange.
  • The settlement is expected to close no earlier than five business days from August 19, 2026.

6ix AI wrote this summary from the release below and checked it against the release.

TORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, announces a proposed debt settlement pursuant to which the Company intends to issue up to 1,221,516 common shares in the capital of the Company (the "Settlement Shares") at a deemed price of $0.05 per Settlement Share to settle an aggregate of $61,061 in outstanding trade payables owing to two arm's length creditors of the Company (the "Debt Settlement").

The Settlement Shares will be issued in accordance with the policies of the Canadian Securities Exchange (the "CSE"). All Settlement Shares issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws. Completion of the Debt Settlement remains subject to certain conditions, including receipt of all necessary regulatory approvals, including approval of the CSE.

The Debt Settlement is expected to close no earlier than five business days from the date of this news release and remains subject to CSE acceptance

About Revive Therapeutics Ltd.

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. For more information, visit www.revivethera.com.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1-888-901-0036
Email: mfrank@revivethera.com
Website: www.revivethera.com

SOURCE: Revive Therapeutics Ltd.

View the original press release on ACCESS Newswire

View original source (ACCESS Newswire)Revive Therapeutics Ltd. on 6ix

Story so far

Earlier from Revive Therapeutics

Later from Revive Therapeutics

All Revive Therapeutics news releases